GSK committed $270 million up front in recent months to gain access to early-stage assets in the class of cancer therapies known as antibody drug conjugates, or ADCs. The deals are part of a broad ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback